{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:13:54Z","timestamp":1786990434058,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Thrombosis Research Institute"},{"name":"Bayer Pharma AG"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.ijcard.2016.08.236","type":"journal-article","created":{"date-parts":[[2016,8,15]],"date-time":"2016-08-15T03:49:26Z","timestamp":1471232966000},"page":"543-547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry"],"prefix":"10.1016","volume":"223","author":[{"given":"Seil","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Accetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantep","family":"Angchaisuksiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. John","family":"Camm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Cools","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Kayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Koretsune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toon Wei","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Misselwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"van Eickels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Kakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2016.08.236_bb0005","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archinte.1994.00420130036007","volume":"154","year":"1994","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ijcard.2016.08.236_bb0010","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.107.750000","article-title":"Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range","volume":"118","author":"Connolly","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.08.236_bb0015","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/europace\/eus305","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation\u2013developed with the special contribution of the European Heart Rhythm Association","volume":"14","author":"Camm","year":"2012","journal-title":"Europace"},{"key":"10.1016\/j.ijcard.2016.08.236_bb0020","first-page":"e199","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.08.236_bb0025","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.joa.2013.03.002","article-title":"The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation","volume":"29","author":"Ogawa","year":"2013","journal-title":"J. Arrhythm."},{"key":"10.1016\/j.ijcard.2016.08.236_bb0030","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1253\/circj.CJ-66-0092","article-title":"Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013)","volume":"78","author":"J. C. S. Joint Working Group","year":"2014","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcard.2016.08.236_bb0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ahj.2011.09.011","article-title":"International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)","author":"Kakkar","year":"2012","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2016.08.236_bb0040","series-title":"Composition of Macro Geographical (Continental) Regions, Geographical Sub-regions, and Selected Economic and Other Groupings","year":"2013"},{"key":"10.1016\/j.ijcard.2016.08.236_bb0045","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ahj.2014.06.005","article-title":"Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial","volume":"168","author":"Goto","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2016.08.236_bb0050","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/STROKEAHA.113.000990","article-title":"Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation","volume":"44","author":"Hori","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2016.08.236_bb0055","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1161\/STROKEAHA.113.000883","article-title":"Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis","volume":"44","author":"Albertsen","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2016.08.236_bb0060","series-title":"Working Group Report: Stroke Prevention in Patients With Atrial Fibrillation","article-title":"How can we avoid a stroke crisis in the Asia-Pacific region?","author":"Goto","year":"2011"},{"key":"10.1016\/j.ijcard.2016.08.236_bb0065","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1253\/circj.CJ-13-0290","article-title":"Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM Registry","volume":"77","author":"Inoue","year":"2013","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcard.2016.08.236_bb0070","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2257.2006.00757.x","article-title":"Prevalence of factor V Leiden and prothrombin G20210A mutations in Chinese patients with deep venous thrombosis and pulmonary embolism","volume":"28","author":"Jun","year":"2006","journal-title":"Clin. Lab. Haematol."},{"key":"10.1016\/j.ijcard.2016.08.236_bb0075","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1055\/s-0037-1614913","article-title":"The factor V Leiden mutation and the prothrombin G20210A mutation was not found in Japanese patients with pulmonary thromboembolism","volume":"82","author":"Ro","year":"1999","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2016.08.236_bb0080","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0049-3848(96)00034-5","article-title":"Absence of factor V Leiden in the Japanese","volume":"81","author":"Ozawa","year":"1996","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ijcard.2016.08.236_bb0085","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1253\/circj.CJ-14-0144","article-title":"Validation of CHA2DS2-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation: an analysis of the J-RHYTHM Registry","volume":"78","author":"Okumura","year":"2014","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcard.2016.08.236_bb0090","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.000067","article-title":"Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial","author":"Singer","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2016.08.236_bb0095","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/ha.2010.002691","volume":"3","author":"Goto","year":"2011","journal-title":"Heart Asia."},{"key":"10.1016\/j.ijcard.2016.08.236_bb0100","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jacc.2007.01.098","article-title":"Racial\/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation","volume":"50","author":"Shen","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.08.236_bb0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10928-009-9138-4","article-title":"Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin","volume":"37","author":"Yuen","year":"2010","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ijcard.2016.08.236_bb0110","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clpt.2004.05.005","article-title":"Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose","volume":"76","author":"Zhao","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ijcard.2016.08.236_bb0115","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/01.STR.19.1.48","article-title":"Intracerebral hemorrhage in a Japanese community, Hisayama: incidence, changing pattern during long-term follow-up, and related factors","volume":"19","author":"Ueda","year":"1988","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2016.08.236_bb0120","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1177\/0091270008319794","article-title":"Same drug, different dosing: differences in dosing for drugs approved in the United States, Europe, and Japan","volume":"48","author":"Malinowski","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2016.08.236_bb0125","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrcardio.2014.104","article-title":"Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI","volume":"11","author":"Levine","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ijcard.2016.08.236_bb0130","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation \u2014 the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ. J."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316319428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316319428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:36:27Z","timestamp":1759091787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527316319428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":26,"alternative-id":["S0167527316319428"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.08.236","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.08.236","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}